Program
enzalutamide
Also written as “Enzalutamide”, “MDV3100” and “HC-1119”.
Its studies are mostly in Prostatic Neoplasms · Neoplasms · Breast Neoplasms · Prostatic Neoplasms, Castration-Resistant · Neoplasm Metastasis, led by 6 companies.
Drug pageEnzalutamide: every studyMany companies study it; this page follows only the 54 they lead. All 176 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Astellas Pharmaits history only | 313 open or running | phase 4since Oct 31, 2013 | Jan 18, 2011 | Apr 30, 2027phase 1 · NCT07783282 |
| Pfizer | 162 open or running | phase 4since Nov 18, 2013 | Jul 31, 2007 | none ahead |
| Hinova Pharmaceuticalsits history only | 41 open or running | phase 3since Feb 17, 2019 | Dec 11, 2018 | none ahead |
| Alessa Therapeuticsits history only | 11 open or running | phase 1since Dec 14, 2023 | Dec 14, 2023 | Dec 30, 2028phase 1 · NCT06257693 |
| Applied Biologyits history only | 10 open or running | phase 3since Jul 28, 2021 | Jul 28, 2021 | none ahead |
| Hinova Pharmaceuticals USAits history only | 10 open or running | phase 3since Feb 20, 2019 | Feb 20, 2019 | none ahead |
Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Johnson & Johnson, Medivation LLC, a wholly owned subsidiary of Pfizer and Gilead Sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Pfizer only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Jul 31, 2007.
- Mar 19, 2010Phase 2 study in Metastatic Progressive Castration-resistant Prostate CancerNCT01091103 · 60 enrolled · United States
- Sep 29, 2010Phase 3 study in Prostatic NeoplasmsNCT01212991 · 1,717 enrolled · United States, Australia, Austria and more
- Feb 8, 2012Phase 1 study in Prostatic NeoplasmsNCT01565928 · 23 enrolled · United States
- Feb 27, 2012Phase 2 study in Prostatic NeoplasmsNCT01547299 · 52 enrolled · United States, Canada
- May 9, 2012Phase 1 study in Breast NeoplasmsNCT01597193 · 101 enrolled · United States
- Aug 10, 2012Phase 2 study in Prostatic NeoplasmsNCT01664923 · 396 enrolled · United States
- Jun 26, 2013Phase 2 study in Breast NeoplasmsNCT01889238 · 118 enrolled · United States, Belgium, Canada and more
- Nov 18, 2013Phase 4 study in Prostatic NeoplasmsNCT01995513 · 509 enrolled · United States, Australia, Belgium and more
- Dec 3, 2013Phase 2 study in Breast NeoplasmsNCT02007512 · 247 enrolled · United States, Belgium, Canada and more
- Dec 3, 2013Phase 3 study in Prostatic NeoplasmsNCT02003924 · 1,401 enrolled · United States, Argentina, Australia and more
- Dec 14, 2014Phase 3 study in Prostatic NeoplasmsNCT02319837 · 1,068 enrolled · United States, Australia, Austria and more
- Mar 4, 2015Phase 2 study in Prostatic NeoplasmsNCT02384382 · 23 enrolled · United States
- Sep 7, 2016Phase 3 study in Breast NeoplasmsNCT02929576 · United States
- Mar 25, 2021Phase 3 study in Prostatic NeoplasmsNCT04821622 · 599 enrolled · United States, Argentina, Australia and more
TargetBeta
“A deuterated form of enzalutamide, an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) ”NCIt, by rule
“Androgen Receptor antagonist”ChEMBL 37, by rule
Other programs on AR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| apalutamiderule | Johnson & Johnson | phase 4 | 31 |
| darolutamiderule | Bayer | phase 4 | 26 |
| Clascoteronerule | cassiopea-spa | phase 4 | 19 |
| ostarinerule | gtx | phase 3 | 15 |
| rezvilutamiderule | Jiangsu HengRui Medicine | phase 3 | 13 |
| dezandrodegrule | Bristol-Myers Squibb | phase 3 | 5 |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 4 |
| Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 | Johnson & Johnson | phase 3 | 3 |
| HRS-5041 | Jiangsu HengRui Medicine | phase 2 | 6 |
| luxdegalutamide | Novartis | phase 2 | 3 |
| luxdegalutamide | Novartis | phase 2 | 2 |
| Androgen Receptor Degrader AZD9750rule | AstraZeneca | phase 2 | 1 |
Studies
All 16 Pfizer leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04821622Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Feb 18, 2026 | 599 |
| NCT02929576Breast Neoplasms · United States | 3 | Withdrawn | Apr 2019 | 0 |
| NCT02384382Prostatic Neoplasms · United States | 2 | Completed | May 3, 2019 | 23 |
| NCT02319837Prostatic Neoplasms · United States, Australia, Austria and more | 3 | Active, not recruiting | Jan 31, 2023 | 1,068 |
| NCT02007512Breast Neoplasms · United States, Belgium, Canada and more | 2 | Completed | Sep 23, 2016 | 247 |
| NCT02003924Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Jun 28, 2017 | 1,401 |
| NCT01995513Prostatic Neoplasms · United States, Australia, Belgium and more | 4 | Completed | Nov 15, 2016 | 509 |
| NCT01889238Breast Neoplasms · United States, Belgium, Canada and more | 2 | Completed | Mar 1, 2015 | 118 |
| NCT01664923Prostatic Neoplasms · United States | 2 | Completed | Feb 2015 | 396 |
| NCT01597193Breast Neoplasms · United States | 1 | Completed | Dec 15, 2015 | 101 |
| NCT01547299Prostatic Neoplasms · United States, Canada | 2 | Completed | Nov 30, 2013 | 52 |
| NCT01565928Prostatic Neoplasms · United States | 1 | Completed | Jul 1, 2013 | 23 |
| NCT01212991Prostatic Neoplasms · United States, Australia, Austria and more | 3 | Completed | Sep 30, 2013 | 1,717 |
| NCT01091103Metastatic Progressive Castration-resistant Prostate Cancer · United States | 2 | Completed | Feb 29, 2012 | 60 |
| NCT00974311Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Sep 15, 2011 | 1,199 |
| NCT00510718Prostatic Neoplasms · United States | 1 | Completed | Dec 8, 2008 | 140 |
How it is read
Names in the registry
- “Enzalutamide”, 40 entries
- “enzalutamide”, 13 entries
- “MDV3100”, 8 entries
- “HC-1119”, 4 entries
- “HC1119”, 2 entries
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 41 studies
- Neoplasms, 6 studies
- Breast Neoplasms, 5 studies
- Prostatic Neoplasms, Castration-Resistant, 2 studies
- Neoplasm Metastasis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.